Jonathon Cohen
Professor, Co-Director of Lymphoma Program
Emory University / Winship Cancer Institute · Atlanta, United States
MCL investigator at Winship Cancer Institute focused on novel therapeutic combinations for relapsed and refractory MCL.
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025.
Cancer · Apr 15, 2026
[Blastoïd mantle cell lymphoma, TdT-positive: Toward a more juvenile profile?].
Annales de pathologie · Apr 15, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.
Blood advances · Feb 24, 2026
Real-world treatment patterns, patient characteristics, and outcomes of initial cBTKi-based therapies in second-line or later amongst a contemporary cohort of patients with MCL in the United States.
Leukemia & lymphoma · Feb 24, 2026
Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center.
Current oncology (Toronto, Ont.) · May 20, 2025
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Haematologica · Jan 1, 2025
Is rituximab retro in mantle cell lymphoma?
Blood · Jul 18, 2024
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
British journal of haematology · Jan 1, 2024